[Risk factors for the development of recurrences in patients with breast carcinoma without axillary lymph node metastases].
The influence of a number of risk factors on development of tumour recurrence was studied retrospectively in a group of breast cancer patients without axillary lymph node metastases, all treated identically and with long follow-ups. Of 71 patients all data could be retrieved. This group had a median duration of follow-up of five years. Thirteen patients (18.3%) had had a recurrence of carcinoma after a median disease-free period of 41 months (range 3-124 months). These patients at the time when breast cancer was diagnosed had had a lower median age than patients who had remained free of tumour recurrence, 48 (40-70) as against 59.5 (30-81) years. Factors having a statistically significant prognostic importance for recurrence of tumour were age at the time of diagnosis of breast carcinoma, histological tumour grade and nuclear DNA content. Identifying groups of patients with a higher or lower risk of tumour recurrence appears possible by combination of risk factors. Although patients with breast cancer without axillary lymph node metastases are supposed to have a favourable prognosis, there appear to exist subgroups with a raised risk for development of a recurrence. These groups might be prime candidates for prospective randomized studies of the usefulness of adjuvant therapy.
Akkersdijk
W L
WL
Afd. Chirurgie, Academisch Ziekenhuis, Utrecht.
Pieters
J H
JH
Smits
J G
JG
de Kruif
J T
JT
van der Tweel
I
I
de Graaf
P W
PW
D000328:Adult; D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry / Q000145:classification / Q000473:pathology*; D004273:DNA, Neoplasm / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors
D004273:DNA, Neoplasm
Risicofactoren voor het ontstaan van recidieven bij patiënten met een mammacarcinoom zonder okselkliermetastasen.